UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________
FORM 8-K
_____________
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): August 1, 2017
 
TG Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction
of Incorporation)
001-32639
(Commission File Number)
 
36-3898269
(IRS Employer Identification No.)
 
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address of Principal Executive Offices)
 
(212) 554-4484
(Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 ☐
Written communications pursuant to Rule 425 under the Securities Act.
 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
 ☐
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
 ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
 
 
 
Item 8.01. Other Events.
 
   On August 1, 2017, TG Therapeutics, Inc. (the “Company”) issued a press release announcing it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of two Phase 3 clinical trials for TG-1101 (ublituximab), the Company’s glycoengineered anti-CD20 monoclonal antibody, for the treatment of relapsing forms of Multiple Sclerosis (RMS). A copy of the press release is being filed as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01 Financial Statements And Exhibits.
 
(d) Exhibits.
 
99.1  Press Release, dated August 1, 2017.

 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
TG Therapeutics, Inc.
 
(Registrant)
 
 
 
 
 
 
Date: August 1, 2017
 
 
By: /s/ Sean A. Power             
 
Sean A. Power
 
Chief Financial Officer
 
 
 
 
 
 
 
 
INDEX TO EXHIBITS
 
 
 
 
Exhibit
 
 
Number
 
Description
 
 
 
99.1
 
Press Release, dated August 1, 2017.